In addition, angiotensin II (Ang II) dysregulation was determined in many cardiovascular diseases, and it could upregulate CX3CR1 expression in VSMCs via the NADPH oxidase/ROS/p38 MAPK pathway [31]. This evidence concerns the gene FMO5 and cardiovascular disorder.